Molecular mechanisms of B-lymphocyte transformation by Epstein–Barr virus

Thorley-Lawson, 2001, EBV: exploiting the immune system, Nat. Rev. Immunol., 1, 75, 10.1038/35095584 Wensing, 2000, Regulation of cell growth and death by EBV, Microbes Infect., 2, 77, 10.1016/S1286-4579(00)00282-3 Howie, 2000, The gene defective in XLP controls T cell dependent immune surveillance against EBV, Curr. Opin. Immunol., 12, 474, 10.1016/S0952-7915(00)00123-0 Rowe, 1999, EBV immortalization and latency, Frontiers Biosci., 4, d346, 10.2741/Rowe Hammerschmidt, 1989, Genetic analysis of immortalizing functions of EBV in human B lymphocytes, Nature, 340, 393, 10.1038/340393a0 Yates, 1985, Stable replication of plasmids derived from EBV in various mammalian cells, Nature, 313, 812, 10.1038/313812a0 Livitskaya, 1997, Inhibition of ubiquitin/proteasome-dependent protein degradation by the gly–ala repeat domain of EBNA-1, Proc. Natl. Acad. Sci. USA, 94, 12616, 10.1073/pnas.94.23.12616 Mackey, 1999, The linking regions of EBNA1 are essential for its support of replication and transcription, Mol. Cell. Biol., 19, 3349, 10.1128/MCB.19.5.3349 Wilson, 1996, Expression of EBNA-1 induces B cell neoplasia in transgenic mice, EMBO J., 15, 3117, 10.1002/j.1460-2075.1996.tb00674.x Tong, 1995, The EBNA-2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein, J. Virol., 69, 585, 10.1128/jvi.69.1.585-588.1995 Laux, 1994, The Spi-1/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-Jκ interact with an EBNA2-responsive cis-element, EMBO J., 13, 5624, 10.1002/j.1460-2075.1994.tb06900.x Tornell, 1996, Expression of EBNA-2 in kidney tubule cells induces tumors in transgenic mice, Oncogene, 12, 1521 Tomkinson, 1993, EBNA 3A and 3C are essential for B lymphocyte growth transformation, J. Virol., 67, 5068, 10.1128/jvi.67.4.2014-2025.1993 Kaye, 1993, EBV LMP1 is essential for B-lymphocyte growth transformation: EBV strategy in normal and neoplastic B cells, Proc. Natl. Acad. Sci. USA, 90, 9150, 10.1073/pnas.90.19.9150 Kulwichit, 1998, Expression of the EBV LMP1 induces B cell lymphoma in transgenic mice, Proc. Natl. Acad. Sci. USA, 95, 11963, 10.1073/pnas.95.20.11963 Zimber-Strobl, 1996, EBV LMP1 is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival, EMBO J., 15, 7070, 10.1002/j.1460-2075.1996.tb01098.x Busch, 1999, The EBV transforming protein, LMP1, mimics and cooperates with CD40 signaling in B lymphocytes, J. Immunol., 162, 2555, 10.4049/jimmunol.162.5.2555 Bishop, 2001, Signaling by CD40 and its mimics in B cell activation, Immunol. Res., 24, 97, 10.1385/IR:24:2:097 Kaykas, 2001, CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex, EMBO J., 20, 2641, 10.1093/emboj/20.11.2641 Hostager, 2000, Recruitment of CD40, TRAF2 and TRAF3 to membrane microdomains during CD40 signaling, J. Biol. Chem., 275, 15392, 10.1074/jbc.M909520199 Brown, 2001, Differential signaling and TRAF degradation by CD40 and the EBV oncoprotein LMP1, J. Exp. M, 193, 943, 10.1084/jem.193.8.943 Busch, 2001, Multiple carboxyl-terminal regions of the EBV oncoprotein, J. Immunol., 167, 5805, 10.4049/jimmunol.167.10.5805 Sandberg, 1997, Characterization of LMP1 association with TRAF1, 2 and 3, J. Virol., 71, 4649, 10.1128/jvi.71.6.4649-4656.1997 Izumi, 1999, The residues between the two transformation effector sites of EBV LMP1 are not critical for B lymphocyte growth transformation, J. Virol., 73, 9908, 10.1128/JVI.73.12.9908-9916.1999 Miller, 1994, An integral membrane protein (LMP2) blocks reactivation of EBV from latency following surface Ig crosslinking, Proc. Natl. Acad. Sci. USA, 91, 772, 10.1073/pnas.91.2.772 Dykstra, 2001, EBV coopts lipid rafts to block the signaling and antigen transport functions of the BCR, Immunity, 14, 57, 10.1016/S1074-7613(01)00089-9 Ikeda, 2001, PY motifs of EBV LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins, J. Virol., 75, 5711, 10.1128/JVI.75.12.5711-5718.2001 Engels, 2001, EBV LMP2A employs the SLP-65 signaling module, J. Exp. M, 194, 255, 10.1084/jem.194.3.255 Caldwell, 1998, EBV LMP2A drives B cell development and survival in the absence of normal BCR signals, Immunity, 9, 405, 10.1016/S1074-7613(00)80623-8 Haan, 2001, Establishment of latent EBV infection and stable episomal maintenance in murine B-cell lines, J. Virol., 75, 3016, 10.1128/JVI.75.6.3016-3020.2001